Article
Mutant p53 exploits enhancers to elevate immunosuppressive chemokine expression and impair immune checkpoint inhibitors in pancreatic cancer.
Immunity - 8 Jul 2025
Mahat Dig B, Kumra Heena, Castro Sarah A, Metcalf Emily, Nguyen Kim, Morisue Ryo, Ho William W, Chen Ivy, Sullivan Brandon, Yim Leon H, Singh Arundeep, Fu Jiayu, Waterton Sean K, Cheng Yu-Chi, Moiso Enrico, Chauhan Vikash P, Silva Hernandez Moura, Spranger Stefani, Jain Rakesh K, Sharp Phillip A
Abstract excerpt
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer characterized by activating KRAS mutations and TP53 alterations. TP53 missense mutations lose their wild-type tumor-suppressor function. Here, we studied whether p53 missense mutations have potential gain-of-function oncogenic roles and their impact on cancer-cell-intrinsic gene expression and the tumor immune microenvironment (TME) in PDAC....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.